nodes	percent_of_prediction	percent_of_DWPC	metapath
Sulindac—MAPK3—atherosclerosis	0.484	0.797	CbGaD
Sulindac—PTGS2—atherosclerosis	0.0651	0.107	CbGaD
Sulindac—ALB—atherosclerosis	0.058	0.0955	CbGaD
Sulindac—SLC22A6—Pravastatin—atherosclerosis	0.0411	0.516	CbGbCtD
Sulindac—ALB—Rosuvastatin—atherosclerosis	0.0384	0.483	CbGbCtD
Sulindac—MAPK3—artery—atherosclerosis	0.00372	0.102	CbGeAlD
Sulindac—MAPK3—endothelium—atherosclerosis	0.00314	0.0861	CbGeAlD
Sulindac—MAPK3—blood vessel—atherosclerosis	0.0029	0.0794	CbGeAlD
Sulindac—AKR1B1—connective tissue—atherosclerosis	0.00205	0.0562	CbGeAlD
Sulindac—AKR1B1—cardiovascular system—atherosclerosis	0.00178	0.0489	CbGeAlD
Sulindac—PTGS2—leg—atherosclerosis	0.00177	0.0484	CbGeAlD
Sulindac—PTGS2—hindlimb—atherosclerosis	0.00158	0.0432	CbGeAlD
Sulindac—AKR1B1—adipose tissue—atherosclerosis	0.00157	0.0431	CbGeAlD
Sulindac—MAPK3—connective tissue—atherosclerosis	0.00149	0.0407	CbGeAlD
Sulindac—PTGS2—appendage—atherosclerosis	0.00135	0.0371	CbGeAlD
Sulindac—MAPK3—cardiovascular system—atherosclerosis	0.00129	0.0354	CbGeAlD
Sulindac—PPARD—adipose tissue—atherosclerosis	0.00124	0.0339	CbGeAlD
Sulindac—MAPK3—adipose tissue—atherosclerosis	0.00114	0.0312	CbGeAlD
Sulindac—AKR1B1—liver—atherosclerosis	0.0011	0.0302	CbGeAlD
Sulindac—PTGS1—artery—atherosclerosis	0.00101	0.0277	CbGeAlD
Sulindac—PTGS2—artery—atherosclerosis	0.000967	0.0265	CbGeAlD
Sulindac—PPARD—liver—atherosclerosis	0.000868	0.0238	CbGeAlD
Sulindac—PTGS1—endothelium—atherosclerosis	0.000854	0.0234	CbGeAlD
Sulindac—PTGS2—endothelium—atherosclerosis	0.000817	0.0224	CbGeAlD
Sulindac—MAPK3—liver—atherosclerosis	0.0008	0.0219	CbGeAlD
Sulindac—PTGS1—blood vessel—atherosclerosis	0.000788	0.0216	CbGeAlD
Sulindac—PTGS2—blood vessel—atherosclerosis	0.000753	0.0206	CbGeAlD
Sulindac—PTGS1—connective tissue—atherosclerosis	0.000404	0.0111	CbGeAlD
Sulindac—PTGS2—connective tissue—atherosclerosis	0.000386	0.0106	CbGeAlD
Sulindac—ALB—liver—atherosclerosis	0.000381	0.0104	CbGeAlD
Sulindac—Hepatitis—Ezetimibe—atherosclerosis	0.000367	0.00259	CcSEcCtD
Sulindac—Photosensitivity reaction—Pravastatin—atherosclerosis	0.000361	0.00255	CcSEcCtD
Sulindac—Erythema multiforme—Lovastatin—atherosclerosis	0.000354	0.0025	CcSEcCtD
Sulindac—CYP1A1—adipose tissue—atherosclerosis	0.000353	0.00966	CbGeAlD
Sulindac—Depression—Pravastatin—atherosclerosis	0.000352	0.00248	CcSEcCtD
Sulindac—PTGS1—cardiovascular system—atherosclerosis	0.000351	0.00963	CbGeAlD
Sulindac—Angioedema—Rosuvastatin—atherosclerosis	0.000351	0.00248	CcSEcCtD
Sulindac—Hepatitis—Simvastatin—atherosclerosis	0.00035	0.00247	CcSEcCtD
Sulindac—Stevens-Johnson syndrome—Pravastatin—atherosclerosis	0.00035	0.00247	CcSEcCtD
Sulindac—Stomatitis—Niacin—atherosclerosis	0.000349	0.00246	CcSEcCtD
Sulindac—Jaundice—Niacin—atherosclerosis	0.000349	0.00246	CcSEcCtD
Sulindac—Flushing—Lovastatin—atherosclerosis	0.000347	0.00245	CcSEcCtD
Sulindac—Erythema multiforme—Ezetimibe—atherosclerosis	0.000347	0.00245	CcSEcCtD
Sulindac—Neuropathy peripheral—Pravastatin—atherosclerosis	0.000346	0.00244	CcSEcCtD
Sulindac—Jaundice—Pravastatin—atherosclerosis	0.000344	0.00242	CcSEcCtD
Sulindac—Sweating—Niacin—atherosclerosis	0.000343	0.00242	CcSEcCtD
Sulindac—Flushing—Ezetimibe—atherosclerosis	0.000341	0.0024	CcSEcCtD
Sulindac—PTGS2—cardiovascular system—atherosclerosis	0.000336	0.0092	CbGeAlD
Sulindac—Chills—Lovastatin—atherosclerosis	0.000336	0.00237	CcSEcCtD
Sulindac—Erythema multiforme—Simvastatin—atherosclerosis	0.000331	0.00233	CcSEcCtD
Sulindac—Alopecia—Lovastatin—atherosclerosis	0.000331	0.00233	CcSEcCtD
Sulindac—Myalgia—Rosuvastatin—atherosclerosis	0.000327	0.00231	CcSEcCtD
Sulindac—Arthralgia—Rosuvastatin—atherosclerosis	0.000327	0.00231	CcSEcCtD
Sulindac—Flushing—Simvastatin—atherosclerosis	0.000325	0.00229	CcSEcCtD
Sulindac—Alopecia—Ezetimibe—atherosclerosis	0.000324	0.00229	CcSEcCtD
Sulindac—Hepatitis—Niacin—atherosclerosis	0.000321	0.00227	CcSEcCtD
Sulindac—Flatulence—Lovastatin—atherosclerosis	0.000321	0.00226	CcSEcCtD
Sulindac—Dysgeusia—Lovastatin—atherosclerosis	0.000319	0.00225	CcSEcCtD
Sulindac—Hepatitis—Pravastatin—atherosclerosis	0.000317	0.00223	CcSEcCtD
Sulindac—Flatulence—Ezetimibe—atherosclerosis	0.000315	0.00222	CcSEcCtD
Sulindac—Chills—Simvastatin—atherosclerosis	0.000314	0.00222	CcSEcCtD
Sulindac—PTGS1—adipose tissue—atherosclerosis	0.00031	0.00849	CbGeAlD
Sulindac—Visual impairment—Niacin—atherosclerosis	0.00031	0.00218	CcSEcCtD
Sulindac—Alopecia—Simvastatin—atherosclerosis	0.000309	0.00218	CcSEcCtD
Sulindac—Thrombocytopenia—Rosuvastatin—atherosclerosis	0.000307	0.00217	CcSEcCtD
Sulindac—Vision blurred—Lovastatin—atherosclerosis	0.000307	0.00217	CcSEcCtD
Sulindac—Visual impairment—Pravastatin—atherosclerosis	0.000305	0.00215	CcSEcCtD
Sulindac—Ill-defined disorder—Lovastatin—atherosclerosis	0.000302	0.00213	CcSEcCtD
Sulindac—Flatulence—Simvastatin—atherosclerosis	0.0003	0.00212	CcSEcCtD
Sulindac—Tinnitus—Niacin—atherosclerosis	0.0003	0.00211	CcSEcCtD
Sulindac—Erythema multiforme—Pravastatin—atherosclerosis	0.000299	0.00211	CcSEcCtD
Sulindac—Dysgeusia—Simvastatin—atherosclerosis	0.000298	0.0021	CcSEcCtD
Sulindac—Flushing—Niacin—atherosclerosis	0.000298	0.0021	CcSEcCtD
Sulindac—Angioedema—Lovastatin—atherosclerosis	0.000298	0.0021	CcSEcCtD
Sulindac—Ill-defined disorder—Ezetimibe—atherosclerosis	0.000297	0.00209	CcSEcCtD
Sulindac—PTGS2—adipose tissue—atherosclerosis	0.000296	0.00811	CbGeAlD
Sulindac—Anaemia—Ezetimibe—atherosclerosis	0.000295	0.00208	CcSEcCtD
Sulindac—Tinnitus—Pravastatin—atherosclerosis	0.000295	0.00208	CcSEcCtD
Sulindac—Malaise—Lovastatin—atherosclerosis	0.000294	0.00207	CcSEcCtD
Sulindac—Flushing—Pravastatin—atherosclerosis	0.000294	0.00207	CcSEcCtD
Sulindac—Vertigo—Lovastatin—atherosclerosis	0.000293	0.00206	CcSEcCtD
Sulindac—Angioedema—Ezetimibe—atherosclerosis	0.000292	0.00206	CcSEcCtD
Sulindac—Leukopenia—Lovastatin—atherosclerosis	0.000292	0.00206	CcSEcCtD
Sulindac—Chills—Niacin—atherosclerosis	0.000288	0.00203	CcSEcCtD
Sulindac—Malaise—Ezetimibe—atherosclerosis	0.000288	0.00203	CcSEcCtD
Sulindac—Vision blurred—Simvastatin—atherosclerosis	0.000287	0.00203	CcSEcCtD
Sulindac—Arrhythmia—Niacin—atherosclerosis	0.000287	0.00203	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Rosuvastatin—atherosclerosis	0.000286	0.00202	CcSEcCtD
Sulindac—Alopecia—Niacin—atherosclerosis	0.000284	0.002	CcSEcCtD
Sulindac—Chills—Pravastatin—atherosclerosis	0.000284	0.002	CcSEcCtD
Sulindac—Insomnia—Rosuvastatin—atherosclerosis	0.000284	0.002	CcSEcCtD
Sulindac—Ill-defined disorder—Simvastatin—atherosclerosis	0.000283	0.00199	CcSEcCtD
Sulindac—Arrhythmia—Pravastatin—atherosclerosis	0.000283	0.00199	CcSEcCtD
Sulindac—Palpitations—Ezetimibe—atherosclerosis	0.000282	0.00199	CcSEcCtD
Sulindac—Paraesthesia—Rosuvastatin—atherosclerosis	0.000282	0.00199	CcSEcCtD
Sulindac—Anaemia—Simvastatin—atherosclerosis	0.000282	0.00199	CcSEcCtD
Sulindac—Alopecia—Pravastatin—atherosclerosis	0.00028	0.00197	CcSEcCtD
Sulindac—Angioedema—Simvastatin—atherosclerosis	0.000278	0.00196	CcSEcCtD
Sulindac—Chest pain—Lovastatin—atherosclerosis	0.000277	0.00196	CcSEcCtD
Sulindac—Arthralgia—Lovastatin—atherosclerosis	0.000277	0.00196	CcSEcCtD
Sulindac—Myalgia—Lovastatin—atherosclerosis	0.000277	0.00196	CcSEcCtD
Sulindac—Dyspepsia—Rosuvastatin—atherosclerosis	0.000276	0.00195	CcSEcCtD
Sulindac—Hypertension—Ezetimibe—atherosclerosis	0.000276	0.00195	CcSEcCtD
Sulindac—Flatulence—Niacin—atherosclerosis	0.000276	0.00194	CcSEcCtD
Sulindac—Malaise—Simvastatin—atherosclerosis	0.000275	0.00194	CcSEcCtD
Sulindac—Tension—Niacin—atherosclerosis	0.000275	0.00194	CcSEcCtD
Sulindac—Discomfort—Lovastatin—atherosclerosis	0.000274	0.00193	CcSEcCtD
Sulindac—Vertigo—Simvastatin—atherosclerosis	0.000274	0.00193	CcSEcCtD
Sulindac—Leukopenia—Simvastatin—atherosclerosis	0.000273	0.00192	CcSEcCtD
Sulindac—Arthralgia—Ezetimibe—atherosclerosis	0.000272	0.00192	CcSEcCtD
Sulindac—Myalgia—Ezetimibe—atherosclerosis	0.000272	0.00192	CcSEcCtD
Sulindac—Chest pain—Ezetimibe—atherosclerosis	0.000272	0.00192	CcSEcCtD
Sulindac—Nervousness—Niacin—atherosclerosis	0.000272	0.00192	CcSEcCtD
Sulindac—Flatulence—Pravastatin—atherosclerosis	0.000272	0.00191	CcSEcCtD
Sulindac—Tension—Pravastatin—atherosclerosis	0.00027	0.00191	CcSEcCtD
Sulindac—Dysgeusia—Pravastatin—atherosclerosis	0.00027	0.0019	CcSEcCtD
Sulindac—Discomfort—Ezetimibe—atherosclerosis	0.000269	0.0019	CcSEcCtD
Sulindac—Constipation—Rosuvastatin—atherosclerosis	0.000268	0.00189	CcSEcCtD
Sulindac—Nervousness—Pravastatin—atherosclerosis	0.000268	0.00189	CcSEcCtD
Sulindac—Anaphylactic shock—Lovastatin—atherosclerosis	0.000266	0.00188	CcSEcCtD
Sulindac—Vision blurred—Niacin—atherosclerosis	0.000264	0.00186	CcSEcCtD
Sulindac—Anaphylactic shock—Ezetimibe—atherosclerosis	0.000261	0.00184	CcSEcCtD
Sulindac—Thrombocytopenia—Lovastatin—atherosclerosis	0.00026	0.00184	CcSEcCtD
Sulindac—Vision blurred—Pravastatin—atherosclerosis	0.00026	0.00183	CcSEcCtD
Sulindac—Myalgia—Simvastatin—atherosclerosis	0.000259	0.00183	CcSEcCtD
Sulindac—Chest pain—Simvastatin—atherosclerosis	0.000259	0.00183	CcSEcCtD
Sulindac—Arthralgia—Simvastatin—atherosclerosis	0.000259	0.00183	CcSEcCtD
Sulindac—Feeling abnormal—Rosuvastatin—atherosclerosis	0.000259	0.00182	CcSEcCtD
Sulindac—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.000257	0.00181	CcSEcCtD
Sulindac—Discomfort—Simvastatin—atherosclerosis	0.000256	0.00181	CcSEcCtD
Sulindac—Angioedema—Niacin—atherosclerosis	0.000256	0.0018	CcSEcCtD
Sulindac—Ill-defined disorder—Pravastatin—atherosclerosis	0.000256	0.0018	CcSEcCtD
Sulindac—Thrombocytopenia—Ezetimibe—atherosclerosis	0.000255	0.0018	CcSEcCtD
Sulindac—Anaemia—Pravastatin—atherosclerosis	0.000255	0.0018	CcSEcCtD
Sulindac—Anorexia—Lovastatin—atherosclerosis	0.000253	0.00179	CcSEcCtD
Sulindac—Angioedema—Pravastatin—atherosclerosis	0.000252	0.00178	CcSEcCtD
Sulindac—Vertigo—Niacin—atherosclerosis	0.000251	0.00177	CcSEcCtD
Sulindac—Syncope—Niacin—atherosclerosis	0.000251	0.00177	CcSEcCtD
Sulindac—CYP1A2—liver—atherosclerosis	0.000251	0.00687	CbGeAlD
Sulindac—Leukopenia—Niacin—atherosclerosis	0.00025	0.00177	CcSEcCtD
Sulindac—Urticaria—Rosuvastatin—atherosclerosis	0.000249	0.00176	CcSEcCtD
Sulindac—Anaphylactic shock—Simvastatin—atherosclerosis	0.000249	0.00175	CcSEcCtD
Sulindac—Oedema—Simvastatin—atherosclerosis	0.000249	0.00175	CcSEcCtD
Sulindac—Malaise—Pravastatin—atherosclerosis	0.000248	0.00175	CcSEcCtD
Sulindac—Vertigo—Pravastatin—atherosclerosis	0.000248	0.00175	CcSEcCtD
Sulindac—CYP1A1—liver—atherosclerosis	0.000247	0.00678	CbGeAlD
Sulindac—Palpitations—Niacin—atherosclerosis	0.000247	0.00174	CcSEcCtD
Sulindac—Leukopenia—Pravastatin—atherosclerosis	0.000247	0.00174	CcSEcCtD
Sulindac—Loss of consciousness—Niacin—atherosclerosis	0.000246	0.00173	CcSEcCtD
Sulindac—Thrombocytopenia—Simvastatin—atherosclerosis	0.000244	0.00172	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Lovastatin—atherosclerosis	0.000242	0.00171	CcSEcCtD
Sulindac—Insomnia—Lovastatin—atherosclerosis	0.000241	0.0017	CcSEcCtD
Sulindac—Paraesthesia—Lovastatin—atherosclerosis	0.000239	0.00168	CcSEcCtD
Sulindac—Arthralgia—Niacin—atherosclerosis	0.000238	0.00168	CcSEcCtD
Sulindac—Myalgia—Niacin—atherosclerosis	0.000238	0.00168	CcSEcCtD
Sulindac—Hypertension—Pravastatin—atherosclerosis	0.000238	0.00168	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Ezetimibe—atherosclerosis	0.000238	0.00168	CcSEcCtD
Sulindac—Anorexia—Simvastatin—atherosclerosis	0.000237	0.00167	CcSEcCtD
Sulindac—Dyspnoea—Lovastatin—atherosclerosis	0.000237	0.00167	CcSEcCtD
Sulindac—Insomnia—Ezetimibe—atherosclerosis	0.000236	0.00166	CcSEcCtD
Sulindac—Chest pain—Pravastatin—atherosclerosis	0.000235	0.00165	CcSEcCtD
Sulindac—Myalgia—Pravastatin—atherosclerosis	0.000235	0.00165	CcSEcCtD
Sulindac—Arthralgia—Pravastatin—atherosclerosis	0.000235	0.00165	CcSEcCtD
Sulindac—Paraesthesia—Ezetimibe—atherosclerosis	0.000234	0.00165	CcSEcCtD
Sulindac—Dyspepsia—Lovastatin—atherosclerosis	0.000234	0.00165	CcSEcCtD
Sulindac—Dyspnoea—Ezetimibe—atherosclerosis	0.000233	0.00164	CcSEcCtD
Sulindac—Discomfort—Pravastatin—atherosclerosis	0.000232	0.00163	CcSEcCtD
Sulindac—Hypersensitivity—Rosuvastatin—atherosclerosis	0.000231	0.00163	CcSEcCtD
Sulindac—Decreased appetite—Lovastatin—atherosclerosis	0.000231	0.00163	CcSEcCtD
Sulindac—Dyspepsia—Ezetimibe—atherosclerosis	0.00023	0.00162	CcSEcCtD
Sulindac—Fatigue—Lovastatin—atherosclerosis	0.000229	0.00162	CcSEcCtD
Sulindac—Anaphylactic shock—Niacin—atherosclerosis	0.000228	0.00161	CcSEcCtD
Sulindac—Oedema—Niacin—atherosclerosis	0.000228	0.00161	CcSEcCtD
Sulindac—Constipation—Lovastatin—atherosclerosis	0.000227	0.0016	CcSEcCtD
Sulindac—Decreased appetite—Ezetimibe—atherosclerosis	0.000227	0.0016	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Simvastatin—atherosclerosis	0.000227	0.0016	CcSEcCtD
Sulindac—Asthenia—Rosuvastatin—atherosclerosis	0.000225	0.00159	CcSEcCtD
Sulindac—Insomnia—Simvastatin—atherosclerosis	0.000225	0.00159	CcSEcCtD
Sulindac—Anaphylactic shock—Pravastatin—atherosclerosis	0.000225	0.00159	CcSEcCtD
Sulindac—Oedema—Pravastatin—atherosclerosis	0.000225	0.00159	CcSEcCtD
Sulindac—Fatigue—Ezetimibe—atherosclerosis	0.000225	0.00159	CcSEcCtD
Sulindac—Shock—Niacin—atherosclerosis	0.000225	0.00158	CcSEcCtD
Sulindac—Paraesthesia—Simvastatin—atherosclerosis	0.000223	0.00158	CcSEcCtD
Sulindac—Constipation—Ezetimibe—atherosclerosis	0.000223	0.00157	CcSEcCtD
Sulindac—Tachycardia—Niacin—atherosclerosis	0.000223	0.00157	CcSEcCtD
Sulindac—Pruritus—Rosuvastatin—atherosclerosis	0.000222	0.00157	CcSEcCtD
Sulindac—Dyspnoea—Simvastatin—atherosclerosis	0.000222	0.00156	CcSEcCtD
Sulindac—Hyperhidrosis—Niacin—atherosclerosis	0.000221	0.00156	CcSEcCtD
Sulindac—Thrombocytopenia—Pravastatin—atherosclerosis	0.00022	0.00155	CcSEcCtD
Sulindac—Feeling abnormal—Lovastatin—atherosclerosis	0.000219	0.00155	CcSEcCtD
Sulindac—Dyspepsia—Simvastatin—atherosclerosis	0.000219	0.00154	CcSEcCtD
Sulindac—Anorexia—Niacin—atherosclerosis	0.000218	0.00154	CcSEcCtD
Sulindac—Gastrointestinal pain—Lovastatin—atherosclerosis	0.000217	0.00153	CcSEcCtD
Sulindac—Hyperhidrosis—Pravastatin—atherosclerosis	0.000217	0.00153	CcSEcCtD
Sulindac—Decreased appetite—Simvastatin—atherosclerosis	0.000216	0.00152	CcSEcCtD
Sulindac—Feeling abnormal—Ezetimibe—atherosclerosis	0.000215	0.00152	CcSEcCtD
Sulindac—Diarrhoea—Rosuvastatin—atherosclerosis	0.000215	0.00151	CcSEcCtD
Sulindac—Fatigue—Simvastatin—atherosclerosis	0.000214	0.00151	CcSEcCtD
Sulindac—Anorexia—Pravastatin—atherosclerosis	0.000214	0.00151	CcSEcCtD
Sulindac—Hypotension—Niacin—atherosclerosis	0.000213	0.00151	CcSEcCtD
Sulindac—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.000213	0.0015	CcSEcCtD
Sulindac—Constipation—Simvastatin—atherosclerosis	0.000213	0.0015	CcSEcCtD
Sulindac—Urticaria—Lovastatin—atherosclerosis	0.000211	0.00149	CcSEcCtD
Sulindac—Body temperature increased—Lovastatin—atherosclerosis	0.00021	0.00148	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Niacin—atherosclerosis	0.000208	0.00147	CcSEcCtD
Sulindac—PTGS2—liver—atherosclerosis	0.000208	0.00569	CbGeAlD
Sulindac—Dizziness—Rosuvastatin—atherosclerosis	0.000207	0.00146	CcSEcCtD
Sulindac—Urticaria—Ezetimibe—atherosclerosis	0.000207	0.00146	CcSEcCtD
Sulindac—Insomnia—Niacin—atherosclerosis	0.000207	0.00146	CcSEcCtD
Sulindac—Body temperature increased—Ezetimibe—atherosclerosis	0.000206	0.00145	CcSEcCtD
Sulindac—Paraesthesia—Niacin—atherosclerosis	0.000205	0.00145	CcSEcCtD
Sulindac—Feeling abnormal—Simvastatin—atherosclerosis	0.000205	0.00145	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Pravastatin—atherosclerosis	0.000205	0.00144	CcSEcCtD
Sulindac—Dyspnoea—Niacin—atherosclerosis	0.000204	0.00144	CcSEcCtD
Sulindac—Gastrointestinal pain—Simvastatin—atherosclerosis	0.000203	0.00143	CcSEcCtD
Sulindac—Insomnia—Pravastatin—atherosclerosis	0.000203	0.00143	CcSEcCtD
Sulindac—Somnolence—Niacin—atherosclerosis	0.000203	0.00143	CcSEcCtD
Sulindac—Paraesthesia—Pravastatin—atherosclerosis	0.000202	0.00142	CcSEcCtD
Sulindac—Dyspepsia—Niacin—atherosclerosis	0.000201	0.00142	CcSEcCtD
Sulindac—Dyspnoea—Pravastatin—atherosclerosis	0.0002	0.00141	CcSEcCtD
Sulindac—Decreased appetite—Niacin—atherosclerosis	0.000199	0.0014	CcSEcCtD
Sulindac—Dyspepsia—Pravastatin—atherosclerosis	0.000198	0.0014	CcSEcCtD
Sulindac—Rash—Rosuvastatin—atherosclerosis	0.000198	0.0014	CcSEcCtD
Sulindac—Dermatitis—Rosuvastatin—atherosclerosis	0.000198	0.00139	CcSEcCtD
Sulindac—Urticaria—Simvastatin—atherosclerosis	0.000198	0.00139	CcSEcCtD
Sulindac—Body temperature increased—Simvastatin—atherosclerosis	0.000197	0.00139	CcSEcCtD
Sulindac—Headache—Rosuvastatin—atherosclerosis	0.000197	0.00139	CcSEcCtD
Sulindac—Hypersensitivity—Lovastatin—atherosclerosis	0.000196	0.00138	CcSEcCtD
Sulindac—Decreased appetite—Pravastatin—atherosclerosis	0.000195	0.00138	CcSEcCtD
Sulindac—Fatigue—Pravastatin—atherosclerosis	0.000194	0.00137	CcSEcCtD
Sulindac—Constipation—Pravastatin—atherosclerosis	0.000192	0.00136	CcSEcCtD
Sulindac—Hypersensitivity—Ezetimibe—atherosclerosis	0.000192	0.00136	CcSEcCtD
Sulindac—Asthenia—Lovastatin—atherosclerosis	0.000191	0.00135	CcSEcCtD
Sulindac—Pruritus—Lovastatin—atherosclerosis	0.000188	0.00133	CcSEcCtD
Sulindac—Asthenia—Ezetimibe—atherosclerosis	0.000187	0.00132	CcSEcCtD
Sulindac—Gastrointestinal pain—Niacin—atherosclerosis	0.000187	0.00132	CcSEcCtD
Sulindac—Nausea—Rosuvastatin—atherosclerosis	0.000186	0.00131	CcSEcCtD
Sulindac—Feeling abnormal—Pravastatin—atherosclerosis	0.000185	0.00131	CcSEcCtD
Sulindac—Pruritus—Ezetimibe—atherosclerosis	0.000185	0.0013	CcSEcCtD
Sulindac—Gastrointestinal pain—Pravastatin—atherosclerosis	0.000184	0.0013	CcSEcCtD
Sulindac—Hypersensitivity—Simvastatin—atherosclerosis	0.000183	0.00129	CcSEcCtD
Sulindac—Diarrhoea—Lovastatin—atherosclerosis	0.000182	0.00128	CcSEcCtD
Sulindac—Urticaria—Niacin—atherosclerosis	0.000181	0.00128	CcSEcCtD
Sulindac—Body temperature increased—Niacin—atherosclerosis	0.000181	0.00127	CcSEcCtD
Sulindac—Urticaria—Pravastatin—atherosclerosis	0.000179	0.00126	CcSEcCtD
Sulindac—Asthenia—Simvastatin—atherosclerosis	0.000178	0.00126	CcSEcCtD
Sulindac—Diarrhoea—Ezetimibe—atherosclerosis	0.000178	0.00126	CcSEcCtD
Sulindac—Body temperature increased—Pravastatin—atherosclerosis	0.000178	0.00125	CcSEcCtD
Sulindac—Pruritus—Simvastatin—atherosclerosis	0.000176	0.00124	CcSEcCtD
Sulindac—Dizziness—Lovastatin—atherosclerosis	0.000176	0.00124	CcSEcCtD
Sulindac—Dizziness—Ezetimibe—atherosclerosis	0.000172	0.00122	CcSEcCtD
Sulindac—Diarrhoea—Simvastatin—atherosclerosis	0.00017	0.0012	CcSEcCtD
Sulindac—Vomiting—Lovastatin—atherosclerosis	0.000169	0.00119	CcSEcCtD
Sulindac—Hypersensitivity—Niacin—atherosclerosis	0.000168	0.00119	CcSEcCtD
Sulindac—Rash—Lovastatin—atherosclerosis	0.000168	0.00118	CcSEcCtD
Sulindac—Dermatitis—Lovastatin—atherosclerosis	0.000168	0.00118	CcSEcCtD
Sulindac—Headache—Lovastatin—atherosclerosis	0.000167	0.00117	CcSEcCtD
Sulindac—Vomiting—Ezetimibe—atherosclerosis	0.000166	0.00117	CcSEcCtD
Sulindac—Hypersensitivity—Pravastatin—atherosclerosis	0.000166	0.00117	CcSEcCtD
Sulindac—Dizziness—Simvastatin—atherosclerosis	0.000164	0.00116	CcSEcCtD
Sulindac—Rash—Ezetimibe—atherosclerosis	0.000164	0.00116	CcSEcCtD
Sulindac—Dermatitis—Ezetimibe—atherosclerosis	0.000164	0.00116	CcSEcCtD
Sulindac—Asthenia—Niacin—atherosclerosis	0.000164	0.00116	CcSEcCtD
Sulindac—Headache—Ezetimibe—atherosclerosis	0.000163	0.00115	CcSEcCtD
Sulindac—Pruritus—Niacin—atherosclerosis	0.000162	0.00114	CcSEcCtD
Sulindac—Asthenia—Pravastatin—atherosclerosis	0.000161	0.00114	CcSEcCtD
Sulindac—Pruritus—Pravastatin—atherosclerosis	0.000159	0.00112	CcSEcCtD
Sulindac—Vomiting—Simvastatin—atherosclerosis	0.000158	0.00112	CcSEcCtD
Sulindac—Nausea—Lovastatin—atherosclerosis	0.000158	0.00111	CcSEcCtD
Sulindac—Rash—Simvastatin—atherosclerosis	0.000157	0.00111	CcSEcCtD
Sulindac—Dermatitis—Simvastatin—atherosclerosis	0.000157	0.00111	CcSEcCtD
Sulindac—Diarrhoea—Niacin—atherosclerosis	0.000156	0.0011	CcSEcCtD
Sulindac—Headache—Simvastatin—atherosclerosis	0.000156	0.0011	CcSEcCtD
Sulindac—Nausea—Ezetimibe—atherosclerosis	0.000155	0.00109	CcSEcCtD
Sulindac—Diarrhoea—Pravastatin—atherosclerosis	0.000154	0.00109	CcSEcCtD
Sulindac—Dizziness—Niacin—atherosclerosis	0.000151	0.00107	CcSEcCtD
Sulindac—Dizziness—Pravastatin—atherosclerosis	0.000149	0.00105	CcSEcCtD
Sulindac—Nausea—Simvastatin—atherosclerosis	0.000148	0.00104	CcSEcCtD
Sulindac—Vomiting—Niacin—atherosclerosis	0.000145	0.00102	CcSEcCtD
Sulindac—Rash—Niacin—atherosclerosis	0.000144	0.00102	CcSEcCtD
Sulindac—Dermatitis—Niacin—atherosclerosis	0.000144	0.00101	CcSEcCtD
Sulindac—Headache—Niacin—atherosclerosis	0.000143	0.00101	CcSEcCtD
Sulindac—Vomiting—Pravastatin—atherosclerosis	0.000143	0.00101	CcSEcCtD
Sulindac—Rash—Pravastatin—atherosclerosis	0.000142	0.001	CcSEcCtD
Sulindac—Dermatitis—Pravastatin—atherosclerosis	0.000142	0.000999	CcSEcCtD
Sulindac—Headache—Pravastatin—atherosclerosis	0.000141	0.000994	CcSEcCtD
Sulindac—Nausea—Niacin—atherosclerosis	0.000136	0.000957	CcSEcCtD
Sulindac—Nausea—Pravastatin—atherosclerosis	0.000134	0.000942	CcSEcCtD
Sulindac—CYP1A2—Metabolism—ABCG1—atherosclerosis	7.22e-06	5.36e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—PLA2G1B—atherosclerosis	7.22e-06	5.36e-05	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—IL6—atherosclerosis	7.18e-06	5.33e-05	CbGpPWpGaD
Sulindac—ALB—Transmembrane transport of small molecules—PPARA—atherosclerosis	7.15e-06	5.31e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—MMP3—atherosclerosis	7.14e-06	5.3e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—APOE—atherosclerosis	7.14e-06	5.3e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—IGF2—atherosclerosis	7.11e-06	5.27e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—SCARB1—atherosclerosis	7.1e-06	5.26e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—PIK3CG—atherosclerosis	7.07e-06	5.25e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—CAV1—atherosclerosis	7.07e-06	5.25e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CG—atherosclerosis	7.07e-06	5.24e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—APOA1—atherosclerosis	7.05e-06	5.23e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—ALOX5—atherosclerosis	6.97e-06	5.17e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism of lipids and lipoproteins—ALB—atherosclerosis	6.91e-06	5.13e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—APOB—atherosclerosis	6.9e-06	5.12e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—NAMPT—atherosclerosis	6.86e-06	5.09e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism of lipids and lipoproteins—PPARG—atherosclerosis	6.82e-06	5.06e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—LIPC—atherosclerosis	6.82e-06	5.06e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—EDN1—atherosclerosis	6.79e-06	5.04e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—FABP4—atherosclerosis	6.79e-06	5.04e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—LCAT—atherosclerosis	6.79e-06	5.04e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—APOC3—atherosclerosis	6.77e-06	5.03e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CCL5—atherosclerosis	6.74e-06	5e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—INS—atherosclerosis	6.74e-06	5e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—LDLR—atherosclerosis	6.73e-06	5e-05	CbGpPWpGaD
Sulindac—ALB—Transmembrane transport of small molecules—APOA1—atherosclerosis	6.71e-06	4.98e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—HMGCR—atherosclerosis	6.7e-06	4.97e-05	CbGpPWpGaD
Sulindac—MAPK3—Gene Expression—SERPINE1—atherosclerosis	6.67e-06	4.95e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—APOA4—atherosclerosis	6.66e-06	4.94e-05	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—AKT1—atherosclerosis	6.63e-06	4.92e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—LPL—atherosclerosis	6.59e-06	4.89e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—CETP—atherosclerosis	6.58e-06	4.88e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—CYP7A1—atherosclerosis	6.54e-06	4.86e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—IGF1—atherosclerosis	6.48e-06	4.81e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—HMOX1—atherosclerosis	6.45e-06	4.79e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—PIK3CG—atherosclerosis	6.44e-06	4.78e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—PRKCG—atherosclerosis	6.41e-06	4.75e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—SCARB1—atherosclerosis	6.3e-06	4.67e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—NAMPT—atherosclerosis	6.25e-06	4.64e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—SPP1—atherosclerosis	6.24e-06	4.63e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—APOB—atherosclerosis	6.24e-06	4.63e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—PPARG—atherosclerosis	6.22e-06	4.61e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—CXCL8—atherosclerosis	6.21e-06	4.61e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—LIPC—atherosclerosis	6.21e-06	4.61e-05	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—IL6—atherosclerosis	6.2e-06	4.6e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—SERPINE1—atherosclerosis	6.19e-06	4.59e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—APOB—atherosclerosis	6.18e-06	4.59e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—APOC3—atherosclerosis	6.17e-06	4.58e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—SERPINE1—atherosclerosis	6.15e-06	4.56e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—LDLR—atherosclerosis	6.14e-06	4.55e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism of lipids and lipoproteins—ALB—atherosclerosis	6.13e-06	4.55e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—IFNG—atherosclerosis	6.11e-06	4.53e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—CYP27A1—atherosclerosis	6.05e-06	4.49e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—GSTM1—atherosclerosis	6.01e-06	4.46e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—CETP—atherosclerosis	5.99e-06	4.45e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—ABCA1—atherosclerosis	5.97e-06	4.43e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—LPL—atherosclerosis	5.96e-06	4.42e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—HMGCR—atherosclerosis	5.95e-06	4.41e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—NOS3—atherosclerosis	5.91e-06	4.38e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—LPL—atherosclerosis	5.9e-06	4.38e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—NOS3—atherosclerosis	5.87e-06	4.36e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—APOB—atherosclerosis	5.86e-06	4.35e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—atherosclerosis	5.81e-06	4.31e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—PDGFB—atherosclerosis	5.77e-06	4.28e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—GPX1—atherosclerosis	5.76e-06	4.27e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—SCARB1—atherosclerosis	5.74e-06	4.26e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PLA2G2A—atherosclerosis	5.73e-06	4.25e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—APOA2—atherosclerosis	5.73e-06	4.25e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—ALOX15—atherosclerosis	5.73e-06	4.25e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—ALOX5AP—atherosclerosis	5.73e-06	4.25e-05	CbGpPWpGaD
Sulindac—PPARD—Gene Expression—AKT1—atherosclerosis	5.73e-06	4.25e-05	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—AKT1—atherosclerosis	5.72e-06	4.24e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—ABCG5—atherosclerosis	5.66e-06	4.2e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—CD36—atherosclerosis	5.66e-06	4.2e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—AGT—atherosclerosis	5.64e-06	4.18e-05	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—AKT1—atherosclerosis	5.61e-06	4.16e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—CD36—atherosclerosis	5.61e-06	4.16e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—LPL—atherosclerosis	5.6e-06	4.15e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—LEP—atherosclerosis	5.52e-06	4.1e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—APOE—atherosclerosis	5.52e-06	4.1e-05	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—IL6—atherosclerosis	5.48e-06	4.06e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CAV1—atherosclerosis	5.47e-06	4.06e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—LPA—atherosclerosis	5.47e-06	4.06e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—APOA1—atherosclerosis	5.46e-06	4.05e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—IL1B—atherosclerosis	5.45e-06	4.04e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—PRKCG—atherosclerosis	5.44e-06	4.04e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—HMGCR—atherosclerosis	5.42e-06	4.02e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—PTGS2—atherosclerosis	5.4e-06	4.01e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	5.36e-06	3.98e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—MTHFR—atherosclerosis	5.32e-06	3.94e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—ABCA1—atherosclerosis	5.3e-06	3.93e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—BGN—atherosclerosis	5.3e-06	3.93e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—ESR1—atherosclerosis	5.27e-06	3.91e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—PPARA—atherosclerosis	5.26e-06	3.9e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—APOA5—atherosclerosis	5.24e-06	3.89e-05	CbGpPWpGaD
Sulindac—ALB—Platelet activation, signaling and aggregation—AKT1—atherosclerosis	5.24e-06	3.89e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—PPARA—atherosclerosis	5.21e-06	3.87e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—F2—atherosclerosis	5.21e-06	3.86e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—HMOX1—atherosclerosis	5.12e-06	3.8e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—AGT—atherosclerosis	5.09e-06	3.78e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—NFKB1—atherosclerosis	5.08e-06	3.77e-05	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—AKT1—atherosclerosis	5.05e-06	3.75e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—AGT—atherosclerosis	5.05e-06	3.75e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PLA2G1B—atherosclerosis	5.05e-06	3.75e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—MTHFR—atherosclerosis	5.04e-06	3.74e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—MAPK8—atherosclerosis	4.99e-06	3.71e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—APOE—atherosclerosis	4.99e-06	3.7e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—PIK3CG—atherosclerosis	4.98e-06	3.7e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—APOE—atherosclerosis	4.95e-06	3.67e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—atherosclerosis	4.95e-06	3.67e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—APOA1—atherosclerosis	4.93e-06	3.66e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—APOB—atherosclerosis	4.91e-06	3.64e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—PDGFB—atherosclerosis	4.9e-06	3.64e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—CAV1—atherosclerosis	4.9e-06	3.64e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—APOA1—atherosclerosis	4.89e-06	3.63e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	4.89e-06	3.63e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—ALOX5—atherosclerosis	4.88e-06	3.62e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—ABCA1—atherosclerosis	4.83e-06	3.59e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—GSTM1—atherosclerosis	4.77e-06	3.54e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—INS—atherosclerosis	4.72e-06	3.5e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—APOE—atherosclerosis	4.69e-06	3.48e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—LPL—atherosclerosis	4.69e-06	3.48e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—CAV1—atherosclerosis	4.65e-06	3.45e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CCL2—atherosclerosis	4.64e-06	3.44e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—APOA1—atherosclerosis	4.64e-06	3.44e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—GPX1—atherosclerosis	4.57e-06	3.39e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—STAT3—atherosclerosis	4.57e-06	3.39e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—IGF1—atherosclerosis	4.56e-06	3.39e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—HMOX1—atherosclerosis	4.55e-06	3.37e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—atherosclerosis	4.51e-06	3.34e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—PIK3CG—atherosclerosis	4.47e-06	3.31e-05	CbGpPWpGaD
Sulindac—PPARD—Metabolism—AKT1—atherosclerosis	4.46e-06	3.31e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—CD36—atherosclerosis	4.45e-06	3.3e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—NAMPT—atherosclerosis	4.37e-06	3.25e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—NOS2—atherosclerosis	4.37e-06	3.24e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—APOB—atherosclerosis	4.36e-06	3.23e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—atherosclerosis	4.35e-06	3.23e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—LIPC—atherosclerosis	4.35e-06	3.22e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—SERPINE1—atherosclerosis	4.33e-06	3.22e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—APOC3—atherosclerosis	4.32e-06	3.2e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—PPARG—atherosclerosis	4.31e-06	3.2e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—LDLR—atherosclerosis	4.29e-06	3.19e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—GSTM1—atherosclerosis	4.24e-06	3.14e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—VEGFA—atherosclerosis	4.23e-06	3.14e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—INS—atherosclerosis	4.23e-06	3.14e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—MTHFR—atherosclerosis	4.22e-06	3.13e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—STAT3—atherosclerosis	4.22e-06	3.13e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—CETP—atherosclerosis	4.19e-06	3.11e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—LPL—atherosclerosis	4.16e-06	3.09e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—HMOX1—atherosclerosis	4.15e-06	3.08e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—PPARA—atherosclerosis	4.14e-06	3.07e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—NOS3—atherosclerosis	4.14e-06	3.07e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—GPX1—atherosclerosis	4.06e-06	3.01e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—SCARB1—atherosclerosis	4.02e-06	2.98e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—AGT—atherosclerosis	4.01e-06	2.97e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—INS—atherosclerosis	4.01e-06	2.97e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—MAPK3—atherosclerosis	4e-06	2.97e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—APOB—atherosclerosis	3.97e-06	2.95e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—CD36—atherosclerosis	3.95e-06	2.93e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—APOE—atherosclerosis	3.93e-06	2.91e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—ALB—atherosclerosis	3.91e-06	2.9e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—TGFB1—atherosclerosis	3.91e-06	2.9e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—CAV1—atherosclerosis	3.89e-06	2.89e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—APOA1—atherosclerosis	3.88e-06	2.88e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—TGFB1—atherosclerosis	3.88e-06	2.88e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—ALB—atherosclerosis	3.88e-06	2.88e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—GSTM1—atherosclerosis	3.86e-06	2.87e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—HMGCR—atherosclerosis	3.79e-06	2.81e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—LPL—atherosclerosis	3.79e-06	2.81e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—MTHFR—atherosclerosis	3.75e-06	2.78e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—NOS3—atherosclerosis	3.71e-06	2.75e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—GPX1—atherosclerosis	3.7e-06	2.74e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—SERPINE1—atherosclerosis	3.68e-06	2.73e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—PPARA—atherosclerosis	3.67e-06	2.73e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CXCL8—atherosclerosis	3.67e-06	2.72e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—CD36—atherosclerosis	3.6e-06	2.67e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—AGT—atherosclerosis	3.56e-06	2.64e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—PIK3CG—atherosclerosis	3.55e-06	2.63e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—NOS3—atherosclerosis	3.51e-06	2.61e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—IL6—atherosclerosis	3.49e-06	2.59e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—APOE—atherosclerosis	3.49e-06	2.59e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—CAV1—atherosclerosis	3.45e-06	2.56e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—APOA1—atherosclerosis	3.45e-06	2.56e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—PPARG—atherosclerosis	3.42e-06	2.54e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	3.42e-06	2.54e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—MTHFR—atherosclerosis	3.41e-06	2.53e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—PTGS2—atherosclerosis	3.39e-06	2.52e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—ABCA1—atherosclerosis	3.38e-06	2.51e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—INS—atherosclerosis	3.36e-06	2.49e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—PPARA—atherosclerosis	3.35e-06	2.49e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—MMP9—atherosclerosis	3.32e-06	2.46e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—NFKB1—atherosclerosis	3.28e-06	2.44e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—AGT—atherosclerosis	3.24e-06	2.41e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—MAPK8—atherosclerosis	3.23e-06	2.4e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—AKT1—atherosclerosis	3.22e-06	2.39e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—IL6—atherosclerosis	3.19e-06	2.37e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—APOE—atherosclerosis	3.18e-06	2.36e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—CAV1—atherosclerosis	3.15e-06	2.34e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—PIK3CG—atherosclerosis	3.15e-06	2.33e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—APOA1—atherosclerosis	3.14e-06	2.33e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—ALB—atherosclerosis	3.08e-06	2.28e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—PPARG—atherosclerosis	3.04e-06	2.25e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—VEGFA—atherosclerosis	2.98e-06	2.21e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—INS—atherosclerosis	2.98e-06	2.21e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—STAT3—atherosclerosis	2.95e-06	2.19e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—IL6—atherosclerosis	2.94e-06	2.18e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—NOS3—atherosclerosis	2.94e-06	2.18e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—AKT1—atherosclerosis	2.94e-06	2.18e-05	CbGpPWpGaD
Sulindac—MAPK3—Gene Expression—AKT1—atherosclerosis	2.93e-06	2.17e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—HMOX1—atherosclerosis	2.9e-06	2.15e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—PIK3CG—atherosclerosis	2.87e-06	2.13e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—APOB—atherosclerosis	2.78e-06	2.06e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—PPARG—atherosclerosis	2.77e-06	2.05e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—TGFB1—atherosclerosis	2.74e-06	2.03e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—ALB—atherosclerosis	2.73e-06	2.03e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—AKT1—atherosclerosis	2.72e-06	2.02e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—INS—atherosclerosis	2.72e-06	2.01e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—GSTM1—atherosclerosis	2.7e-06	2e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—AKT1—atherosclerosis	2.7e-06	2e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—LPL—atherosclerosis	2.65e-06	1.97e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—NOS3—atherosclerosis	2.61e-06	1.94e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—GPX1—atherosclerosis	2.59e-06	1.92e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—CD36—atherosclerosis	2.52e-06	1.87e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—STAT3—atherosclerosis	2.51e-06	1.86e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—MAPK3—atherosclerosis	2.4e-06	1.78e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—PTGS2—atherosclerosis	2.39e-06	1.77e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—MTHFR—atherosclerosis	2.39e-06	1.77e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—NOS3—atherosclerosis	2.38e-06	1.77e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PPARA—atherosclerosis	2.34e-06	1.74e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—TGFB1—atherosclerosis	2.32e-06	1.72e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—AGT—atherosclerosis	2.27e-06	1.68e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—APOE—atherosclerosis	2.22e-06	1.65e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—CAV1—atherosclerosis	2.2e-06	1.63e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—APOA1—atherosclerosis	2.2e-06	1.63e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—PTGS2—atherosclerosis	2.18e-06	1.62e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—IL6—atherosclerosis	2.06e-06	1.53e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PIK3CG—atherosclerosis	2.01e-06	1.49e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PPARG—atherosclerosis	1.94e-06	1.44e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—AKT1—atherosclerosis	1.9e-06	1.41e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—INS—atherosclerosis	1.9e-06	1.41e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—IL6—atherosclerosis	1.75e-06	1.3e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—ALB—atherosclerosis	1.74e-06	1.29e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—AKT1—atherosclerosis	1.7e-06	1.26e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—NOS3—atherosclerosis	1.67e-06	1.24e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—AKT1—atherosclerosis	1.62e-06	1.2e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PTGS2—atherosclerosis	1.52e-06	1.13e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—AKT1—atherosclerosis	1.35e-06	1e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—AKT1—atherosclerosis	1.2e-06	8.91e-06	CbGpPWpGaD
Sulindac—ALB—Metabolism—AKT1—atherosclerosis	1.09e-06	8.12e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—AKT1—atherosclerosis	7.66e-07	5.68e-06	CbGpPWpGaD
